Second non-myeloablative allogeneic stem cell transplantation for malignant hematological diseases:a report of 6 cases
- VernacularTitle:二次非清髓异基因造血干细胞移植治疗恶性血液病六例报告
- Author:
Jianhui QIAO
;
Huisheng AI
;
Danhong WANG
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Leukemia
- From:
Chinese Journal of Organ Transplantation
1996;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effects of second non-myeloablative stem cell transplantation (NAST). Methods Six cases of malignant hematological diseases receiving second NAST were retrospectively analyzed. Of them, 3 were suffered from transplant rejection after 1st NAST and the remaining 3 were stable mixed chimerism. Results Five of the patients achieved complete donor's chimerism and have been in disease-free-survival for 6～27 months. 1 GVHD occurred in only one of the 6 patients, and no transplant-related death happened. Conclusion Second NAST is effective for the treatment of patients with transplant rejection,and is also rational choice for those patients with refractory or relapse malignant hematological diseases.
